Figure 1 | Scientific Reports

Figure 1

From: Transition from antigenemia to quantitative nucleic acid amplification testing in cytomegalovirus-seropositive kidney transplant recipients receiving preemptive therapy for cytomegalovirus infection

Figure 1

Flowchart of the population. The transition period is from March 2017 to February 2018, when the service had adopted both methods for viremia detection. CMV, cytomegalovirus; HLA, human leukocyte antigen; mTOR, mammalian target of rapamycin; RT-PCR, real-time polymerase chain reaction.

Back to article page